GLP-1 drugs cost roughly $1,000 a month and a few dollars to make

The GLP-1 drugs behind the weight-loss boom — semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound — carry US list prices around $1,000 a month. A published analysis estimates the actual cost of making this class of drugs is a tiny fraction of that. The distance between the two numbers is not a manufacturing story or a research story. It is a patent story, and in the US the patent has years left to run.

What the drugs cost to make

Researchers estimating "cost-based" prices — what a drug would sell for if priced at the cost of production plus a modest profit — published their analysis in JAMA Network Open in April 2024 [s1]. For the GLP-1 class of medicines, they estimated production costs ranging from $0.75 to $72.49 per month [s1]. Against that, they set the US market price of semaglutide sold as Ozempic: $968.52 a month [s1].

Even taking the high end of the production estimate, that is a price more than thirteen times the cost of making the drug, and at the low end the multiple is in the hundreds. The study's framing is that these drugs could be sold at a large profit for a small fraction of their current price [s1]. This is an estimate, built on ingredient and manufacturing cost data rather than on any manufacturer's actual books, and the companies dispute that such figures capture the true cost of developing and bringing a drug to market. But the order of magnitude — that the gap between price and production cost is enormous — is the study's central and robust point.

Why the price stays high: no competition allowed

A drug's price does not track its production cost while it is protected from competition. Semaglutide and tirzepatide are shielded by patents that bar any other company from selling a copy. With no competitor able to undercut them, and no US regulator setting a ceiling on launch prices, the manufacturers price to what the market and insurers will bear — which, for a drug in overwhelming demand, is high.

The proof that competition, not cost, sets the price is visible the moment the patent falls. In the US, Novo Nordisk's semaglutide patent runs until 2032 [s2]. But in several large countries the patent expired in March 2026 — markets that together hold about a third of the world's adults with obesity — and generic competition arrived almost immediately [s2]. Canada had two generic versions approved as of 1 May 2026, with seven more under review [s2]. Where the branded drug runs more than $1,000 a month, generic versions abroad have been discussed at prices as low as around $14 a month [s2]. The molecule did not get cheaper to make; the legal monopoly simply ended.

What "going off-patent" will and will not do in the US

The international picture is a preview of what US patients can expect — eventually. When semaglutide's US patents lapse and generic or follow-on competitors are allowed in, the price should fall steeply, following the pattern every off-patent drug follows. The caveat is timing. The core US semaglutide patent extends to 2032, and tirzepatide's US patents run several years longer still, with many not beginning to expire until 2036 [s2]. Manufacturers also commonly file layers of additional patents on formulations and delivery devices that can complicate and delay generic entry beyond the expiry of the original molecule patent.

So the honest answer to "when will these get cheap in America" is: not soon, and later than abroad. The drugs that other countries are already getting as low-cost generics remain under US patent protection for years. That is a policy choice embedded in patent law, not a fact about the medicine.

What the evidence supports

The claim that GLP-1 drugs are expensive because they are costly to produce is not supported: the best available estimate puts production cost for the class at under $75 a month against a near-$1,000 US price [s1]. The claim that they are expensive because they are still protected from competition is supported: the same drug becomes dramatically cheaper the moment its patent expires, as it already has in markets outside the US [s2]. For American patients, the practical implication is a wait — US patents on semaglutide and tirzepatide extend into the 2030s, so the low generic prices arriving elsewhere are, for now, elsewhere. This is a description of how drug pricing and patents work, not advice about whether to use these drugs.